Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Prostate cancers initially need the male hormone testosterone for growth. Hormone therapies that lower the level of testosterone are among the best treatments for prostate cancers that have metastasized (spread). The benefits of hormone treatments often do not last, however. Over time, many prostate cancers keep growing even with hormonal therapies. These are called castration-resistant prostate cancers (CRPC).
In addition, their cancers have a fusion (change) in the ALK gene. The fusion gene makes a protein that promotes cancer growth and survival. This type of cancer is called ALK-positive NSCLC.
The purpose of this study is to find the highest dose of the investigational drug NVL-655 that can be given safely in people with advanced non-small cell lung cancer (NSCLC) or other solid tumors that contain a genetic change called an ALK gene fusion. NVL-655 is a type of drug called a tyrosine kinase inhibitor (TKI), which works by blocking proteins that fuel cancer growth. However, some cancer cells develop resistance to TKI treatment.
Prostate cancers initially need the male hormone testosterone for growth. Hormone therapies that lower the level of testosterone are among the best treatments for prostate cancers that have metastasized (spread).
Gemcitabine and oxaliplatin (GemOx) is a standard chemotherapy combination used to treat a cancer of the bile ducts called cholangiocarcinoma. In this study, researchers want to see if adding another treatment that is delivered by a pump device (hepatic arterial infusion or HAI) to GemOx therapy is more effective than GemOx alone for patients with previously untreated inoperable cholangiocarcinoma. The HAI pump, which is implanted in the abdomen during a surgical procedure, continuously delivers the drugs floxuridine and dexamethasone directly to the liver.
However, SBRT may not be enough for people with intermediate-risk prostate cancer and unfavorable genetic features. These features may make it more likely that the cancer will come back after radiation therapy. These people may benefit from SBRT with hormonal therapy early in their care.
Researchers want to find the best dose of ZL-1310 to use in people with advanced digestive tumors. The people in this study have gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) that spread and keeps growing after treatment. These tumors include NEC of the esophagus, stomach, pancreas, gallbladder, or colon/rectum.
Researchers want to find the best dose of LY4170156 to treat people with solid tumors. The people in this study have solid tumors that keep growing even after treatment. Their tumors also make a protein called FRA, which plays a role in cancer growth. The tumors treated in this study include:
Researchers want to find the best dose of NT-175 in people with advanced solid tumors. The people in this study have cancers that are inoperable (cannot be surgically removed) or metastatic (have spread). The types of tumors include:
Researchers are assessing a new combination therapy for neuroblastoma that has a high chance of coming back after treatment. This study is for children with high-risk neuroblastoma who have not gotten more than 1 chemotherapy cycle.
